Ancient Eyptian mummy fungus could be secret to powerful new cancer drug
The notorious Aspergillus flavus - responsible for lung infections in tomb explorers, such as those excavating the final resting place of King Tutankhamen's - may be the unlikely saviour in the fight against leukemia.
University of Pennsylvania scientists have isolated a new class of molecules—asperigimycins—from the fungus.
Two of these compounds, even unmodified, killed leukemia cells in the lab. A third, enhanced with a fatty lipid chain, matched the power of FDA-approved drugs like cytarabine.
These molecules block microtubules - the cell's division machinery - bringing rogue cancer cells to a halt.
The findings were published in a new study in Nature Chemical Biology on Monday (23.06.25).
Sherry Gao - associate professor in chemical and biomolecular engineering and bioengineering at Penn, a senior author on the study - said: "Fungi gave us penicillin. These results show that many more medicines derived from natural products remain to be found.'
'Cancer cells divide uncontrollably. These compounds block the formation of microtubules, which are essential for cell division.'
Scientists from UPenn led a multi-university collaboration in the study along with researchers from Rice, Baylor, Washington University and others.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Australian
8 hours ago
- The Australian
Argenica brain drug paces for FDA clearance
FDA provides clear path for Argenica to lift clinical hold on its ARG-007 stroke drug Further clarification on safety of dose in humans and three additional in vitro lab studies requested Company confident studies are straightforward and can be completed quickly Special Report: Argenica Therapeutics now has a clear path forward to clear the clinical hold currently in place on its investigational new drug application that will enable clinical trials for its lead drug ARG-007. In its full letter, the US Food and Drug Administration (FDA) requested additional information to provide assurance that proposed dosing for a US trial of ARG-007 in acute ischaemic stroke can be achieved safely in humans. The FDA has also requested that Argenica Therapeutics (ASX:AGN) conduct three additional in vitro cell culture studies with clinical research organisations to address identified gaps in data. AGN plans to use safety data from its Phase 2 acute ischaemic stroke trial, which will be available in September, as part of its response to the FDA's request for safety assurance. It adds that three additional studies are small ones that can be completed quickly and build on existing data it has already generated. 'We are pleased to have received the clarification from the FDA as to the additional information required to progress the IND application,' managing director Dr Liz Dallimore said. 'Importantly from a timing and cost perspective, the requested additional in vitro assays are standard assays which are straightforward and efficient to perform. 'Argenica will work with the FDA to ensure the proposed approach to providing the additional information is adequate to lift the clinical hold.' Preventing brain injury During acute neurological events such as stroke, traumatic brain injury (TBI), and hypoxic brain damage, around 1.9 million brain cells die for every minute that blood flow is halted. AGN's ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours by protecting brain tissue during and after these events. The company noted it was targeting acute ischaemic stroke as many patients that experienced it had a thrombectomy, where a radiologist inserts a catheter through the wrist or groin and guides it up into the brain to physically remove a clot. However, this process has the risk of reperfusion injury, which occurs when blood flow rapidly returns to previously oxygen-deprived brain tissue after a clot is removed and potentially causes additional damage. Dosing of patients in a double-blinded, randomised, placebo-controlled Phase 2 trial of ARG-007 in acute ischaemic stroke patients was completed in April. This involved 92 patients presenting to eight emergency departments around Australia with data-read out due in September with safety the main endpoint. The secondary endpoint for the trial will examine efficacy, with a brain scan taken 48 hours post administration of either the placebo or ARG-007. ARG-007 would be the first neuroprotective drug on the global market if approved, tapping into a large addressable global market for stroke and potentially other indications. The global stroke management market was valued at $36.1 billion in 2022, and is projected to reach $74 bn by 2032, driven by several factors including a growing ageing population. There are more than 45,000 strokes annually in Australia and 795,000 in the US – the world's largest healthcare markets. This article was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
News.com.au
3 days ago
- News.com.au
FDA Waiting Room: For Aussie applicants, it's (mainly) business as usual
Despite myriad pressures under the Trump regime, the FDA's drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of device plays awaiting the agency's assent The US Food & Drug Administration's (FDA) resources have been cut more times than Martin Scorsese's then-edgy 1988 religious drama The Last Temptation of Christ. Word from within the powerful agency's imposing Maryland portals is that reviewers have struggled with their task of late because of lack of access to Zoom calls and similar everyday privations. For a legion of Australian drug and device makers awaiting company-making FDA approvals, it's a nervous time. But need they be worried? Business as usual In most cases, the risk of rejection is the same as being struck by lightning. The prevailing message is that despite mayhem at the agency in the Trump era, the approval process has not overly slowed unless the therapy is in a controversial realm (read: vaccines). Rather like the Kyiv denizens carrying out their lives amid a barrage of missiles, it's largely business as usual. A couple of notable rejections aside – namely Replimune Group's melanoma drug RP1, and see the Telix section below – so far this year the FDA has approved therapies for a range of cancers, autoimmune diseases, urinary tract infections and even menopausal hot flushes. PainChek (ASX:PCK) CEO Phil Daffas says the FDA does a 'superb' job under considerable pressure. The developer of a digital pain assessment, Painchek awaits FDA clearance under the de novo (new) device pathway (see below). 'Their M.O. (modus operandi) has been nothing but guidance and support,' he says. Aussie biotechs get the nod ASX life science have-a-go heroes have found favour, especially in the devices and diagnostics realm. In the drug space, the FDA last December greenlit Mesoblast's (ASX:MSB) graft-versus-host disease stem cell treatment, Ryoncil. In June, the agency approved CSL's (ASX:CSL) home-grown Andembry, the world's only prophylactic for hereditary angioedema. Device-wise, the agency approved Orthocell's (ASX:OCC) peripheral nerve repair tool Remplir. It also waved through EBR Systems' (ASX:EBR) groundbreaking left-ventricle assist device Wise and Nanosonics' (ASX:NAN) next-gen medical probe steriliser, Coris. 'Everyone was getting nervous towards the end, but we were very fortunate not to be impacted (by the FDA changes),' Nanosonics chief Michael Kavanagh says. 'The Australian medtech industry should be proud, not necessarily Nanosonics but Australia's ability to do these types of things.' Telix sweats on kidney imaging decision Is the FDA poised to make us further proud? Radiopharmacy giant Telix Pharmaceuticals (ASX:TLX) will know within three weeks whether the FDA has approved its kidney cancer imaging agent, Zircaix. The stakes could not be higher for the $6.8 billion market cap Telix, given Zircaix could well present a bigger market than for Illuccix, its approved prostate cancer imaging agent. So far at least, the FDA hasn't come back with any queries. Mind you, Telix hasn't had its way on other fronts. The FDA in late April knocked back the company's New Drug Application (NDA) for its brain cancer imaging agent, TLX101-CDx. As Telix CEO Dr Chris Behrenbruch pointedly noted, this was despite 'a robust consultation process prior to submission and during review of the NDA'. Painchek's painless process As with Telix, the FDA's decision will be company making for Painchek. Painchek's eponymous app is used across 110,000 nursing home beds in Australia, the UK and Canada – an addressable market of 500,000 beds. The US opens a market of three million beds, worth an estimated $100 million in annual recurring revenue. Painchek's FDA process started in 2019, when the company sought guidance on a supportive clinical trial (since successfully completed). 'The primary contact was the same person all the way through,' Daffas says. Painchek lodged its review in November 2024, after two pre-submission meetings with the agency. 'They recommended a two-step process, with feedback after each step,' he says. 'That was very helpful guidance. If there was room for a misunderstanding it got clarified in those two meetings.' Daffas says the FDA reps included experts in AI, privacy rules and cybersecurity and communications. 'Once again it's very helpful for us, as it makes for a more robust product.' Painchek expects an FDA decision around early October. 4D Medical breathes easy The developer of algo-based lung images tools, 4D Medical (ASX:4DX), has 'frequent flyer' status with the FDA which has approved eight of its devices already. These include its XV LVAS, which processes conventional X-ray scans 'to provide rich, functional lung health detail not available via other modalities'. 4D is now waiting to hear from the FDA about a ventilation perfusion imaging device. The company dubs the FDA's review as 'well progressed'. 4D has filed under the 510(k) predicate device route. According to the company, last year companies waited an average 112 days for an FDA yeah or nay. The current situation is 'aligning well with our experience in previous applications', the company says. Artrya is back for seconds … Artrya (ASX:AYA) says hard-to-detect coronary plaque is a key cause of heart attacks. This was an uncontroversial proposition for the FDA, which in late March approved Artrya's Salix Coronary Anatomy (SCA) platform. The AI-enabled tool provides point-of-care detection of high-risk plaque, a key predictor of heart attacks. Artrya has submitted for approval of a second device, Salix Coronary Plaque (SCP). SCP will extend the use to patients who have undergone a coronary CT angiogram. 'Once cleared, will enable us to deliver near real-time, AI-powered cardiac analysis to a large and growing market and unlock access to an established reimbursement code for plaque analysis,' co-founder (and now CEO) John Konstantopoulos says. The company expects to hear from the FDA by the end of September. … as is Echo IQ As with Artrya, heart diagnosis peer Echo IQ (ASX:EIQ) is no stranger to the FDA. In October last year the agency approved its EchoSolv AS, an AI-inspired device to detect aortic stenosis (narrowing of the heart valves). Echo IQ now is eyeing consent for a second product, EchoSolv HF, to detect heart problems early. It has teamed up with the esteemed Mayo Clinic to carry out a validation trial, the final requirement for FDA submission. Mayo also has exclusive rights to use EchoSolv HF across its 30 hospitals and possibly even co-brand the product. Echo IQ expects FDA approval by the end of the year. Imricor goes modular Still on matters of the heart, Imricor Medical Systems (ASX:IMR) is taking a Lego Masters approach to its maiden FDA application, for its cardiac ablation device, Vision-MR. By this we mean that Imricor has submitted its FDA in separate modules ('bricks'), to enable a rolling review. Vision-MR is the only ablation catheter designed for use with a magnetic resonance imaging (MRI) scanner, as opposed to x-ray fluoroscopy. The company last week said the second module was under review and it expects to submit the third module in the December quarter. 'We expect a steady string of 510(k) product submissions and approvals, which in turn helps accelerate the commercial launch across the US," the company says. In the March quarter European regulators re-approved Vision-MR, under tougher new rules. The European gatekeepers also approved Northstar, 'the world's only MRI-native 3D mapping and guidance system.' The FDA is also likely to approve Northstar in the current half. This will enable the company to start the initial rollout of its interventional cardiac magnetic resonance cardiac ablation labs. Patience, please Some applicants strike trouble with the FDA because they assume that reading the agency's intentions is easy as a Golden Book, when in fact they can be harder to fathom than Ulysses. As Telix's brain cancer setback attests, being on the same page is crucial. Amid the chaos of RFK Jr's early days as health czar, in March your columnist warned that while FDA approvals were often company making, don't expect quick returns. That's because shares may have run hard in anticipation of the happy event and profit takers move in. Often, companies raise capital on positive news and this constrains the share price. EBR did the rounds for $66 million in May and Mesoblast in January raised a monstrous $260 million. FDA approval is only the first step to commercialisation: securing reimbursement and distribution network are just as important. But without consent, companies aren't even in the starting block to tackle the world's richest – albeit more quixotic – healthcare market. If anyone needs reminding, the US accounts for roughly half of the world's healthcare expenditure.
News.com.au
3 days ago
- News.com.au
Health Check: Syntara shares plunge on FDA ‘do more trial homework' edict
Syntara shares tumble almost 50% after the FDA 'suggests' another trial Avita Medical looks to raise capital after a disappointing quarter EBR Systems is on track for limited US launch of its novel heart pacing device Shares in cancer drug developer Syntara (ASX:SNT) this morning lost almost half their value, after unfavourable advice from the US Food & Drug Administration (FDA). The agency has advised the company to do a placebo-controlled phase II trial, before proceeding with a proposed pivotal study for myelofibrosis. As any drug developer would attest, it's always a good idea to take the agency's counsel on board. The FDA wants a placebo-controlled trial to glean "additional safety and efficacy data'. Syntara says the trial should focus on improvements in symptoms and spleen volume reductions, 'in order to optimise the design and efficiency of a subsequent pivotal phase III trial'. Agency takes "conservative" approach CEO Gary Phillips today told investors the company only heard the news on Saturday and was still digesting the implications. 'The FDA has taken a more conservative approach to get the drug to approval,' he says. 'It's not the fast track we were looking for, but nonetheless their guidance is extremely helpful.' In effect, the company can't leapfrog to a planned phase II/III trial, enrolling up to 300 patients at a cost of around US$80 million. The company now is likely to carry out a 90-patient phase 2b study, probably with 60 on active treatment and 30 on placebo. Phillips estimates the cost 'in order of US$25 million', but the study would mean a subsequent phase III trial potentially could be smaller and cheaper. The FDA's stance does blow out the company's time lines, given the phase II effort would take 12 to 18 months to recruit. Ironically, the more circuitous path means lower short-term cash requirements: the company's $15 million should last into 2027, rather than mid 2026 as envisaged. 'The FDA has given us a different clinical path, but everything else around this asset remains the same,' Mr Phillips says. Promising early results The FDA mulled the interim data from Syntara's ongoing phase 1c/2 trial, which tests Syntara's amsulostat (SNT-5505) in combination with the standard-of-care ruxolitinib. Results to date from the open-label study suggest amsulostat 'may deliver deep and long-lasting benefit of patients who are sub optimally controlled by ruxolitinib alone'. Syntara values the myelofibrosis market at US$1 billion a year. Meanwhile, the company expects to release further results from the current open-label trial before the end of September. Reimbursement 'confusion' crimps Avita's sales Friday's poorer-than-expected June quarter result from Avita Medical (ASX:AVH) shows the burns and wounds care pioneer is lagging its revenue and earnings targets, with US reimbursement delays delaying sales from upgraded products. Avita has commercialised Recell for thermal burn wounds and full-thickness skin defects. Unlike other treatments, Recell harnesses the patient's own skin in a spray-on format. In May 2024 the FDA approved Recell Go, which has enhanced features for clinicians. The agency in December then approved Recell Go Mini, for smaller wounds of up to 480 square centimetres. Missing expectations In short, the US rollout has been slower than expected, partly because of reimbursement delays. Bell Potter suggests this resulted from confusion over administration of these payments, which saw physicians not getting paid. There's no Hell like a doctor not being remunerated and they reverted to alternative therapies including skin grafts. Avita posted June quarter revenue of US$18.2 million 20% higher year-on-year but flat on the March quarter tally. The numbers were around 16% below market expectations. June half revenue gained 35% to US$36.5 million. The company lost US$9.9 million in the quarter, compared with a US$15.39 deficit a year ago. Management has trimmed calendar 2025 guidance to US$76-81 million, from the previously guided US$100-106 million. The tally is 19-27% higher year on year. Balance sheet concerns As of June 30, Avita had cash and equivalents of US$15.7 million. It also has a US$40 million debt facility, from specialist lender Orbimed Advisors. The company has won a series of waivers its debt covenants, relating to minimum quarterly and annual revenue. But Avita must continue to maintain a minimum US$10 million of cash. In a 'going concern' note to the accounts, management says that 'absent any mitigating action, the company probably won't be able to comply with a minimum cash balance covenant within the next 12 months. 'The company is actively evaluating strategies to obtain the required additional funding for future operations. This includes an equity raising.' Broker Morgans says 'despite a significant shortfall in sales, Avita successfully rolled through cost-base reductions as planned, decreasing the net loss with more to come in ." Nonetheless, "another missed guidance target is unlikely to reassure investors, and it is now evident that additional capital will be necessary to support the company to profitability.' Rating the stock a 'speculative buy', Morgans forecasts a calendar 2025 loss of US$36.5 million, improving to a US$18.1 million deficit in 2026. Avita then cracks a US$5.6 million profit in 2027. Morgans assumes a US$50 million equity raising. Bell Potter believes the administrative 'confusion' resulted in a 20% drop in demand for Recell over the half – a 'material circa $5 million in lost revenues over the top 10 accounts alone'. The firm says Medicaid patients account for 70-75% of Recell volumes, 'hence it is critical that the matter is resolved without further delay'. Avita shares have tumbled close to 20% since Thursday's close and have lost about two-third of their value since the start of the year. EBR Systems readies US rollout Following a pilot stage, EBR Systems (ASX:EBR) is on track to roll out its novel heart device in the US market in the December quarter. In April the FDA approved WISE, the world's first and only leadless pacing system for heart failure. Addressing a Canaccord Genuity conference in Boston, EBR CEO John McCutcheon said the company would focus on 'strategic' hospitals. Crucially, in October EBR won reimbursement for both inpatient and outpatient settings, at up to US$63,300 per procedure. EBR cites an 'initial addressable market' in the US of US$3.6 billion. In early June EBR announced its first commercial implants, at St David's Medical Centre in Texas and the Cleveland Clinic.
